{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["48(12)"],"submitter":["Graham TE"],"funding":["Tandem Diabetes Care"],"pubmed_abstract":["<h4>Objective</h4>To assess the effect of automated insulin delivery (AID) on glycemic and insulin outcomes in adults with insulin-treated type 2 diabetes using a glucagon-like peptide-1 receptor agonist (GLP-1 RA).<h4>Research design and methods</h4>In a randomized trial comparing Control-IQ+ AID versus continuation of prestudy insulin delivery method plus continuous glucose monitoring (CGM group), 143 (45%) of the 319 participants were using a GLP-1 RA at baseline, which was continued during the trial.<h4>Results</h4>Among GLP-1 RA users, mean HbA1c decreased by 0.8% from a baseline of 8.0 ± 1.2% with AID, which represented a mean improvement of -0.5% (95% CI -0.8 to -0.3, P < 0.001) compared with the CGM group. Time-in-range 70-180 mg/dL and other CGM metrics reflective of hyperglycemia"],"journal":["Diabetes care"],"pagination":["2154-2159"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12635876"],"repository":["biostudies-literature"],"pubmed_title":["Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes."],"pmcid":["PMC12635876"],"pubmed_authors":["Tsoukas M","Tamarez D","Strayer H","Williams J","Estrada K","Spanakis EK","Brouillard E","DiFrancesco K","Kollar L","Herrmann S","Stewart A","Hunter H","Sasson-Katchalski R","Spaic T","Averkiou X","Caswell B","Dalton-Bakes C","Hatipoglu B","Rezac S","Beck RW","Liljenquist DR","Brown SA","Swinton S","Bellini N","Murphy C","Pasqua M","Kollman C","Blevins T","Aia C","Kemp G","Tajrishi FZ","Wolpert H","Holod R","Rickels MR","White K","Ahmann A","Kudva YC","Arroyo LG","Atakov-Castillo A","Kanapka L","Jordan LF","Terry A","Christensen R","Malone J","Lee I","Shao B","Morrell B","Howard Q","Vander-Heide J","Howard M","Phan M","Lum JW","Denallo E","Piquette N","Vancer L","Alabi D","Pasquel FJ","Tsoukas MA","Khakpour D","Haidar A","Kruger D","2IQP Study Group*","Agostini L","Casaubon L","Mitchell T","Becerra M","Rizvi S","Driscoll M","Oliveri M","Curtis S","Bzdick S","Kaur RJ","Payra S","Tardio V","Mellenthin M","Levy CJ","Oladejo O","Coyne K","Kravarusic J","Kamimoto JJ","Jones JK","Hassan S","Morales A","Tribout M","Meeks T","Livingood D","Churchill J","Luker R","Singh L","Costello R","Levister CM","Tribout J","Aleppo G","Layton P","Mukhashen S","Pandit K","Branigan D","Heyerman T","Steenkamp DW","Reyes-Rodriguez C","Davis GM","Ellis E","Bulger J","Peleckis AJ","Le V","Hendricks L","Pinsker JE","Comen K","Ahn D","Campos T","Sullivan A","Emory E","Weinstock RS","Gabrielson D","Lewis C","Carmelo KC","O'Malley G","Wheatcroft A","Corker N","Lesniak A","Sultan R","Schmid C","Spanbauer C","Fronczyk E","Fields C","Fulkerson D","Lapier H","Tessman B","Dhillon J","Litvicov P","Liu S","Graham TE","Penn S","Espinosa V","Scott W","Raskin P","Usman S","Hirsch IB","Raghinaru D","Assir C","Mandava P","Toole E","Rogers J","Cardenas-Villamil G","Perez J","Stone S","Baran J","Desjardins D","Kurek C","Phillips K","Ipek A","Mercado K","Marks S","Dean A","Wolf V","Smith J","DoNguyen T","Holmes V","Hairston B","Ogyaadu S","Fuller M","Oduah V","Bourne P","Dennis B","Moore A","Afreen S","Broyles F","Janicek R"],"additional_accession":[]},"is_claimable":false,"name":"Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes.","description":"<h4>Objective</h4>To assess the effect of automated insulin delivery (AID) on glycemic and insulin outcomes in adults with insulin-treated type 2 diabetes using a glucagon-like peptide-1 receptor agonist (GLP-1 RA).<h4>Research design and methods</h4>In a randomized trial comparing Control-IQ+ AID versus continuation of prestudy insulin delivery method plus continuous glucose monitoring (CGM group), 143 (45%) of the 319 participants were using a GLP-1 RA at baseline, which was continued during the trial.<h4>Results</h4>Among GLP-1 RA users, mean HbA1c decreased by 0.8% from a baseline of 8.0 ± 1.2% with AID, which represented a mean improvement of -0.5% (95% CI -0.8 to -0.3, P < 0.001) compared with the CGM group. Time-in-range 70-180 mg/dL and other CGM metrics reflective of hyperglycemia","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-05-20T03:16:29.151Z","creation":"2026-05-20T03:12:27.025Z"},"accession":"S-EPMC12635876","cross_references":{"pubmed":["41264828"],"doi":["10.2337/dc25-1753"]}}